DAYANG BIOTECH released its performance for the first three quarters, with a net profit attributable to the parent company of 80.366 million yuan, an increase of 56.12%
DAYANG BIOTECH released its Q3 2025 report, with operating revenue for the first three quarters amounting to 747 million yuan, a year-on-year increase of 11.24%. The net profit attributable to the parent company was 80.0366 million yuan, a year-on-year increase of 56.12%. The net profit after deducting non-recurring gains and losses was 74.9836 million yuan, a year-on-year increase of 55.61%. The basic earnings per share were 0.9846 yuan
According to the Zhitong Finance APP, DAYANG BIOTECH (003017.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 747 million yuan, a year-on-year increase of 11.24%. The net profit attributable to shareholders of the listed company was 80.0366 million yuan, a year-on-year increase of 56.12%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 74.9836 million yuan, a year-on-year increase of 55.61%. The basic earnings per share were 0.9846 yuan
